reporting of postprotocol therapies and attrition in multiple myeloma with manni mohyuddin
Published 3 years ago • 504 plays • Length 37:55Download video MP4
Download video MP3
Similar videos
-
27:47
quality of myeloma control arms - lancet haem paper w/ manni mohyuddin
-
1:01:58
multiple myeloma round table - initial therapy, high risk, maintenance
-
25:56
bad karma - an analysis of karmma-3 | idacel vs 'standard regimens'
-
28:23
what questions are current myeloma trials not answering | invited talk to uk myeloma research day
-
29:46
twitter battle - two myeloma doctors debate if we should treat smoldering multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
1:03:25
cancer screening: how testing can find more disease but not make us healthier with gil welch
-
1:28:55
id ethicist zeb jamrozik joins me for 6th discussion| boosters | paxlovid | "my bias is freedom"
-
23:50
myeloma talk | lighthouse, oceans, horizon & more with manni mohhyudin
-
2:01
triplet therapy, transplantation, and maintenance in myeloma | nejm
-
1:02:50
multiple myeloma is a broken field | how i treat frontline | conflicts | 1k rcts but weak evidence
-
24:00
mark lythgoe reporting of race in trials sent to fda
-
19:15
ash update #3 - the ascent trial - dara-krd in smoldering myeloma - it can't assess cure. bad trial
-
42:09
myeloma twitter: makes up unproven medical care | a dangerous hubris
-
5:11
what is the response criteria in myeloma?
-
53:55
how to call out an unethical cancer trial; melflufen; academic oncology w dr. aaron goodman
-
1:54
why consider maintenance therapy if i am in a complete response?
-
2:15
novel immunotherapies for the treatment of multiple myeloma
-
2:08
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
2:01
treatment response of primary tumors and metastases: therapeutics | protocol preview
-
2:24
refinements in mm treatment: a dynamic, ever-evolving field
-
0:58
section 2 how are proteasome inhibitors used in frontline therapy